A multi-institutional experience in the aortic and arterial pathology in individuals with genetically confirmed vascular Ehlers-Danlos syndrome.
Adolescent
Adult
Aged
Aged, 80 and over
Aneurysm
/ epidemiology
Aorta
/ pathology
Arteries
/ pathology
Child
Child, Preschool
Collagen Type III
/ genetics
Cross-Sectional Studies
Ehlers-Danlos Syndrome
/ complications
Embolization, Therapeutic
/ statistics & numerical data
Endovascular Procedures
/ methods
Female
Follow-Up Studies
Genetic Testing
/ statistics & numerical data
Humans
Infant
Male
Middle Aged
Mutation, Missense
Retrospective Studies
Young Adult
Arterial aneurysm
Arterial dissection
Arterial rupture
COL3A1 mutation
Vascular Ehlers-Danlos syndrome
Journal
Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
07
09
2018
accepted:
23
01
2019
pubmed:
28
5
2019
medline:
28
5
2020
entrez:
26
5
2019
Statut:
ppublish
Résumé
Vascular Ehlers-Danlos syndrome (vEDS) is a rare connective tissue disorder owing to pathogenic variants in COL3A1 that lead to impaired type III collagen production. We aim to describe the contemporary multi-institutional experience of aortic and arterial pathology in individuals with vEDS, to evaluate disease patterns and refine management recommendations. This cross-sectional, retrospective study of individuals with genetically confirmed vEDS was conducted between 2000 and 2015 at multiple institutions participating in the Vascular Low Frequency Disease Consortium. Aortic and arterial events including aneurysms, pseudoaneurysms, dissections, fistulae, or ruptures were studied. Demographics, COL3A1 variants, management, and outcomes data were collected and analyzed. Individuals with and without arterial events were compared. Eleven institutions identified 86 individuals with pathogenic variants in COL3A1 (47.7% male, 86% Caucasian; median age, 41 years; interquartile range [IQR], 31.0-49.5 years; 65.1% missense COL3A1 variants). The median follow-up from the time of vEDS diagnosis was 7.5 years (IQR, 3.5-12.0 years). A total of 139 aortic/arterial pathologies were diagnosed in 53 individuals (61.6%; 50.9% male; 88.5% Caucasian; median age, 33 years; IQR, 25.0-42.3 years). The aortic/arterial events presented as an emergency in 52 cases (37.4%). The most commonly affected arteries were the mesenteric arteries (31.7%), followed by cerebrovascular (16.5%), iliac (16.5%), and renal arteries (12.2%). The most common management was medical management. When undertaken, the predominant endovascular interventions were arterial embolization of medium sized arteries (13.4%), followed by stenting (2.5%). Aortic pathology was noted in 17 individuals (32%; 58.8% male; 94.1% Caucasian; median age, 38.5 years; IQR, 30.8-44.7 years). Most notably, four individuals underwent successful abdominal aortic aneurysm repair with excellent results on follow-up. Individuals with missense mutations, in which glycine was substituted with a large amino acid, had an earlier onset of aortic/arterial pathology (median age, 30 years; IQR, 23.5-37 years) compared with the other pathogenic COL3A1 variants (median age, 36 years; IQR, 29.5-44.8 years; P = .065). There were 12 deaths (22.6%) at a median age of 36 years (IQR, 28-51 years). Most of the vEDS arterial manifestations were managed medically in this cohort. When intervention is required for an enlarging aneurysm or rupture, embolization, and less frequently stenting, seem to be well-tolerated. Open repair of abdominal aortic aneurysm seems to be as well-tolerated as in those without vEDS; vEDS should not be a deterrent to offering an operation. Future work to elucidate the role of surgical interventions and refine management recommendations in the context of patient centered outcomes is warranted.
Identifiants
pubmed: 31126764
pii: S0741-5214(19)30337-4
doi: 10.1016/j.jvs.2019.01.069
pmc: PMC8240141
mid: NIHMS1530041
pii:
doi:
Substances chimiques
COL3A1 protein, human
0
Collagen Type III
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1543-1554Subventions
Organisme : NIDDK NIH HHS
ID : K08 DK107934
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000423
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002319
Pays : United States
Informations de copyright
Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.
Références
Proc Natl Acad Sci U S A. 1975 Apr;72(4):1314-6
pubmed: 1055406
Am J Hum Genet. 1997 Dec;61(6):1276-86
pubmed: 9399899
J Vasc Surg. 2018 Aug;68(2):364-371
pubmed: 29567025
Eur J Hum Genet. 2015 Dec;23(12):1657-64
pubmed: 25758994
J Invest Dermatol. 1997 Mar;108(3):241-7
pubmed: 9036918
Br J Haematol. 2009 Jan;144(2):230-3
pubmed: 19036109
Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):40-47
pubmed: 28306228
Lancet. 2010 Oct 30;376(9751):1476-84
pubmed: 20825986
J Neurosurg. 2000 Oct;93(4):689-92
pubmed: 11014550
Cardiovasc Intervent Radiol. 2014 Feb;37(1):77-84
pubmed: 23657781
J Vasc Surg. 2010 Jan;51(1):131-8; discussion 138-9
pubmed: 19879095
Adv Exp Med Biol. 2014;802:129-43
pubmed: 24443025
J Vasc Surg. 2014 Jul;60(1):160-9
pubmed: 24650746
Genet Med. 2011 Aug;13(8):717-22
pubmed: 21637106
Orphanet J Rare Dis. 2018 Jun 25;13(1):100
pubmed: 29940997
Am J Hum Genet. 2001 Nov;69(5):989-1001
pubmed: 11577371
J Vasc Surg. 2007 Jan;45(1):177-9
pubmed: 17210404
Am J Med Genet. 1998 Apr 28;77(1):31-7
pubmed: 9557891
J Biol Chem. 2013 Jun 28;288(26):19166-76
pubmed: 23645670
J Vasc Surg. 2016 Dec;64(6):1869-1880
pubmed: 27687326
N Engl J Med. 2000 Mar 9;342(10):730-2
pubmed: 10706904
Genet Med. 2014 Dec;16(12):881-8
pubmed: 24922459
Ann Vasc Surg. 2012 Jan;26(1):25-33
pubmed: 21945330
Eur J Vasc Endovasc Surg. 2009 Nov;38(5):608-9
pubmed: 19695909
BMJ Case Rep. 2017 Aug 18;2017:
pubmed: 28824011
N Engl J Med. 2000 Mar 9;342(10):673-80
pubmed: 10706896
J Vasc Surg. 2005 Jul;42(1):98-106
pubmed: 16012458
Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):8-26
pubmed: 28306229